Breakthrough in the mechanism of adenoviral gene delivery and new developments to apply the achievement in a clinical setting
| Project/Area Number |
21791298
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
EGAMI Takuya Kyushu University, 医学研究院 (40507787)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2009: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 膵臓外科学 / 膵癌 / ウイルス治療 |
|---|
| Research Abstract |
We revealed that the efficacy of adenoviral therapy was enhanced with combination chemotherapy or radiation. We found that the efficiency of adenoviral therapy in radiation resistant cancer cells was lower than that in radiation sensitive cells, while the efficiency of adenoviral therapy in chemoresistant cancer cells was lower than that in chemosensitive cells. We also revealed that fibroblasts which constitute stroma weaken the efficacy of adenoviral therapy. Furthermore we figured out these mechanisms and identified the molecules responsible for the mechanisms. These data suggest that there are possibilities in adenoviral therapy for individual by evaluating the molecules responsible for adenoviral infection and uptake with respect to each case.
|
Report
(3 results)
Research Products
(16 results)
-
-
-
[Journal Article] Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.2010
Author(s)
Manabu Onimaru, Kenoki Ohuchida, Eishi Nagai, Kazuhiro Mizumoto, Takuya Egami, Lin Cui, Norihiro Sato, Junji Uchino, Koichi Takayama, Makoto Hashizume, Masao Tanaka
-
Journal Title
Cancer Lett 294
Pages: 178-186
Related Report
-
[Journal Article] Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells.2010
Author(s)
Onimaru M, Ohuchida K, Egami T, Mizumoto K, Nagai E, Cui L, Toma H, Matsumoto K, Hashizume M, Tanaka M,
-
Journal Title
Cancer Gene Ther. 17
Pages: 541-549
Related Report
-
-
-
-
-
-
[Journal Article] Adenoviral Therapy Is More Effective in Gemcitabine-resistant Pancreatic Cancer than in Gemcitabine-sensitive Cells.
Author(s)
Takaharu Yasui, Kenoki Ohuchida, Ming Zhao, Lin Cui, Manabu Onimaru, Takuya Egami, Hayato Fujita, Takao Ohtsuka, Kazuhiro Mizumoto, Kunio Matsumoto, Masao Tanaka.
-
Journal Title
Anticancer research. in press
Related Report
-
-
-
-
-
-
